X0508 4 2025-12-01 0001817713 Janux Therapeutics, Inc. JANX 0001864159 Meyer Andrew Hollman C/O JANUX THERAPEUTICS, INC. 10955 VISTA SORRENTO PARKWAY, SUITE 200 SAN DIEGO CA 92130 false true false false Chief Business Officer 1 Common Stock 2025-12-01 4 M 0 3333 10.59 A 88307 D Common Stock 2025-12-01 4 S 0 2700 32.8548 D 85607 D Common Stock 2025-12-01 4 S 0 633 33.5247 D 84974 D Stock Option (right to buy) 10.59 2025-12-01 4 M 0 3333 0 D 2031-05-13 Common Stock 3333 114768 D The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024. The weighted average sale price for the transaction reported was $32.8548 and the range of prices were between $32.27 and $33.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $33.5247 and the range of prices were between $33.28 and $33.92. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Immediately exercisable. /s/ James Pennington, Attorney-in-Fact 2025-12-03